Vaccines have been instrumental in driving material advancements in global health throughout the modern medical era. Intranasal administration of vaccines is an attractive alternative to injections for multiple reasons: * Eliminating needles can reduce anxiety for patients with needle fear or needle fatigue, especially children and those with chronic conditions such as cancer; * Enabling self-administration reduces the burden on healthcare professionals and infrastructure and reduces lost working time for recipients; and * Removing requirements for disposal of needles and the risk of needle-driven cross contamination. Imophoron's proprietary, patent-protected ADDomer technology is particularly suitable for intranasal administration when assessed against competing delivery technologies due to its inherent stability and ability to address multiple infectious diseases. Developing a method for intranasal delivery of ADDomer-based vaccines will enable convenient needle-free delivery targeting a broad range of indications using a single platform. Imophoron's ultimate goal is to enhance vaccine equity and access for all. The funding provided through this programme will be essential in validating an intranasal formulation and delivery device for future ADDomer-based intranasal vaccines, unlocking the next steps in development. Moreover, this programme will serve as a strong foundation for future first-in-human clinical trials. These trials will focus on assessing the safety and tolerability of these innovative vaccines, bringing Imophoron a step closer to delivering much-needed protection to those who urgently need it.